by Johnathan Lancaster, MD, PhD | Mar 24, 2026 | News
The New York Times covered Microsoft’s Copilot Health launch last week. It’s worth reading because it reveals where the entire consumer health AI category stands right now. First, let me say what I genuinely believe: Consumer health AI is one of the most important...
by Johnathan Lancaster, MD, PhD | Feb 24, 2026 | News
Last week, Vinay Prasad and Martin Makary published a landmark piece in the New England Journal of Medicine announcing that the FDA’s new default standard for marketing authorization will be one adequate and well-controlled clinical trial, supported by confirmatory...
by Terry Myerson, CEO | Feb 23, 2026 | News
When the Supreme Court changes a legal standard, the system adjusts. When the FDA changes a regulatory default, the drug development ecosystem recalibrates. Last week’s FDA decision to make one adequate and well-controlled trial the default, supported by confirmatory...
by Johnathan Lancaster, MD, PhD | Jan 26, 2026 | News
Healthcare is changing in front of us. Data, intelligence, and clinical insight are finally converging in ways many of us have been working toward for decades. For the first time, we can begin to understand patient journeys as they actually unfold—not in fragments,...
by Truveta staff | Oct 3, 2025 | News
The US Food and Drug Administration (FDA) recently published a comprehensive overview of how real-world evidence (RWE) has contributed to regulatory decision-making since 2011. The new webpage, built by the Center for Drug Evaluation and Research (CDER) and the Center...
